SCHEDULE 13G: BlackRock Discloses 6.5% Passive Stake in Ginkgo Bioworks Holdings

BlackRock, Inc. has disclosed a passive beneficial ownership of 6.5% of Ginkgo Bioworks Holdings, Inc.'s common stock, totaling over 3 million shares.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,001,643 shares of Ginkgo Bioworks Holdings, Inc. common stock.
• This ownership represents 6.5% of the total outstanding common shares of Ginkgo Bioworks Holdings, Inc.
• BlackRock holds sole voting power over 2,916,224 shares and sole dispositive power over 3,001,643 shares.
• The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The event date requiring this filing was June 30, 2025, and the filing date was July 17, 2025.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of an ownership stake, indicating a neutral sentiment as it does not contain performance data or strategic updates from the issuer.

Positives

• A significant institutional investor, BlackRock, Inc., holds a 6.5% stake, which may be interpreted as a vote of confidence in Ginkgo Bioworks Holdings, Inc.

Negatives

• No negative information regarding Ginkgo Bioworks Holdings, Inc. is disclosed in this ownership filing.

Risks

• No specific risks related to Ginkgo Bioworks Holdings, Inc. are detailed in this ownership disclosure.

Future Outlook

This document does not contain forward-looking statements or guidance from Ginkgo Bioworks Holdings, Inc.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing reflects a major asset manager's passive investment in a biotechnology company, which is a common practice for large institutional funds seeking diversified exposure to various sectors.

Stakeholder Impact

• Shareholders may view BlackRock's significant stake as a positive signal of institutional confidence in Ginkgo Bioworks Holdings, Inc.

Key Dates

Keywords

Ginkgo Bioworks Holdings, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment